BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 23233592)

  • 1. Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies.
    Payen E; Leboulch P
    Hematology Am Soc Hematol Educ Program; 2012; 2012():276-83. PubMed ID: 23233592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
    Persons DA
    Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy Approaches to Hemoglobinopathies.
    Ferrari G; Cavazzana M; Mavilio F
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):835-852. PubMed ID: 28895851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
    Sii-Felice K; Giorgi M; Leboulch P; Payen E
    Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Era for Hemoglobinopathies: More Than One Curative Option.
    Psatha N; Papayanni PG; Yannaki E
    Curr Gene Ther; 2017; 17(5):364-378. PubMed ID: 29357790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy for β-Hemoglobinopathies.
    Cavazzana M; Antoniani C; Miccio A
    Mol Ther; 2017 May; 25(5):1142-1154. PubMed ID: 28377044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
    Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
    Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.
    Segura EER; Ayoub PG; Hart KL; Kohn DB
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Therapy for beta-thalassemia.
    Malik P; Arumugam PI
    Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
    Magrin E; Miccio A; Cavazzana M
    Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
    Dong AC; Rivella S
    Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taking the good out of the bad: lentiviral-based gene therapy of the hemoglobinopathies.
    Stathopulos PB
    Biotechnol Adv; 2003 Sep; 21(6):513-26. PubMed ID: 14499152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Therapy for Hemoglobinopathies: Beta-Thalassemia, Sickle Cell Disease.
    Leonard A; Tisdale JF; Bonner M
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):769-795. PubMed ID: 35773052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
    Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
    PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease.
    Negre O; Bartholomae C; Beuzard Y; Cavazzana M; Christiansen L; Courne C; Deichmann A; Denaro M; de Dreuzy E; Finer M; Fronza R; Gillet-Legrand B; Joubert C; Kutner R; Leboulch P; Maouche L; Paulard A; Pierciey FJ; Rothe M; Ryu B; Schmidt M; von Kalle C; Payen E; Veres G
    Curr Gene Ther; 2015; 15(1):64-81. PubMed ID: 25429463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.
    Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA
    Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell engineering for the treatment of severe hemoglobinopathies.
    Sadelain M; Boulad F; Lisowki L; Moi P; Riviere I
    Curr Mol Med; 2008 Nov; 8(7):690-7. PubMed ID: 18991654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Therapy for Hemoglobinopathies.
    Cavazzana M; Mavilio F
    Hum Gene Ther; 2018 Oct; 29(10):1106-1113. PubMed ID: 30200783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells.
    Papanikolaou E; Georgomanoli M; Stamateris E; Panetsos F; Karagiorga M; Tsaftaridis P; Graphakos S; Anagnou NP
    Hum Gene Ther; 2012 Jan; 23(1):15-31. PubMed ID: 21875313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic cellular gene therapy for hemoglobinopathies.
    Gaziev J; Lucarelli G
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1145-63. PubMed ID: 21075285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.